Educational only — not medical advice. This page explains the published mechanism of a prescription treatment for general education. Botox (onabotulinumtoxinA) is a prescription medicine. It is not FDA-approved for temporomandibular disorders, jaw clenching or bruxism, so the use shown here is off-label. This is not a diagnosis, not a treatment plan, and not a substitute for evaluation by a qualified clinician.
Botox for Jaw Clenching and TMJ: This Time, the Muscle Is the Target
An 80-second narrated mechanism animation on what onabotulinumtoxinA does to the masseter, the muscle that clenches your jaw, with the full transcript and the peer-reviewed references behind every claim — so you can check what the science actually says.
About the drug in this video. Botox (onabotulinumtoxinA) is not FDA-approved for temporomandibular disorders, jaw clenching or bruxism; using it for jaw pain or clenching is off-label.[14,20] As of August 2026 a separate application for jaw slimming (masseter muscle prominence) has been accepted for FDA review; it is under review, not approved.[21] In trials the pain relief is modest and wears off.[10,11,12] Same molecule as the chronic migraine version, a different target: there the sensory nerve endings, here the muscle itself.
Transcript
What the video says, beat by beat
-
Jaw Botox: a muscle that never clocks out
“Your jaw is tired before you're awake. Jaw Botox gets sold as face-slimming. The medical version targets a muscle that never clocks out.”[2,5]
-
The masseter
“The masseter runs from your cheekbone to the corner of your jaw and closes your bite. At night, your brain fires it, not your teeth.”[3,4]
-
Where every clench starts
“Every clench starts at a tiny junction. A nerve ending releases packets of acetylcholine, and the muscle fiber underneath contracts.”[6]
-
This time, the muscle is the target
“Botox cuts a docking protein, SNAP-25, inside that ending, so the packets stay locked and the fiber never gets the order. This time, the muscle is the target.”[6,7]
-
Thinner muscle, tired chewing, then it wears off
“A rested muscle gets thinner, which is the slimming people notice, and chewing tires sooner. Then the nerve sprouts new endings, and the strength returns.”[8,9,15]
-
Rare: uneven smile, hollow cheek. Bone: under study
“Rarely, a smile pulls unevenly or a cheek hollows for a while. Bone under a rested muscle is still being studied. Trouble swallowing or breathing means call your doctor.”[15,16,17,18,19,20]
-
Last resort, not first step
“It's not FDA-approved for jaw pain or clenching, and relief in trials is modest and wears off. A guard, therapy and habit work come first. Educational only. See a specialist.”[20,21,10,11,12,13,14]
“A muscle that never clocks out” is the plain-language version of the definition: bruxism is repetitive jaw-muscle activity — clenching, grinding, bracing — that happens during sleep (rhythmic or not) and while awake.[5] Awake clenching is reported by about one adult in five and sleep bruxism by roughly one in twelve, and the night-time version rides on the brain's sleep micro-arousals rather than on the bite.[3,4] Disorders of the jaw joint itself are common too — about three adults in ten meet research criteria for one — which is why the film separates the muscle from the joint.[1]
What the science says
References
According to PubMed: every journal reference below was verified against its live PubMed record on September 7, 2026; the prescribing-information reference is the current DailyMed label, and the regulatory-status reference is the manufacturer's press release of August 4, 2026. Numeric findings from individual studies are attributed to those studies and are not promises of results. Two references carry industry ties and say so. No clinic-specific dosing appears on this page.
-
Valesan LF, Da-Cas CD, Réus JC, Denardin ACS, Garanhani RR, Bonotto D, Januzzi E, de Souza BDM. Prevalence of temporomandibular joint disorders: a systematic review and meta-analysis. Clin Oral Investig. 2021;25(2):441-453.
Covers: 21 studies using RDC/TMD or DC/TMD criteria — temporomandibular joint disorders in about 31% of adults and elderly people and 11% of children and adolescents, disc displacement with reduction the most common joint diagnosis (25.9%). Painful muscle-type TMD, the film's subject, is usually quoted lower than this joint figure
-
Manfredini D, Winocur E, Guarda-Nardini L, Paesani D, Lobbezoo F. Epidemiology of bruxism in adults: a systematic review of the literature. J Orofac Pain. 2013;27(2):99-110.
Covers: across the usable studies, bruxism of any kind in 8 to 31.4% of adults, awake bruxism in 22.1 to 31%, frequent sleep bruxism in about 12.8%; unrelated to sex, decreasing with age; all self-reported, so the figures are approximate — the “a muscle that never clocks out” beat
-
Lobbezoo F, Naeije M. Bruxism is mainly regulated centrally, not peripherally. J Oral Rehabil. 2001;28(12):1085-1091.
Covers: occlusal discrepancies and bony anatomy play only a small role, if any; bruxism appears to be part of a sleep arousal response modulated by central neurotransmitters — the “at night your brain fires it, not your teeth” beat
PubMed · PMID 11874505 · DOI · 10.1046/j.1365-2842.2001.00839.x
-
Lavigne GJ, Khoury S, Abe S, Yamaguchi T, Raphael K. Bruxism physiology and pathology: an overview for clinicians. J Oral Rehabil. 2008;35(7):476-494.
Covers: awake bruxism (jaw clenching) reported by about 20% of adults and sleep bruxism by about 8%; sleep bruxism classified as a sleep-related movement disorder, secondary to sleep micro-arousals that recur 8 to 14 times per hour of sleep; limited evidence for bite (occlusal) factors — the “sleep arousals” sub-label
PubMed · PMID 18557915 · DOI · 10.1111/j.1365-2842.2008.01881.x
-
Lobbezoo F, Ahlberg J, Raphael KG, Wetselaar P, Glaros AG, Kato T, Santiago V, Winocur E, De Laat A, De Leeuw R, Koyano K, Lavigne GJ, Svensson P, Manfredini D. International consensus on the assessment of bruxism: Report of a work in progress. J Oral Rehabil. 2018;45(11):837-844.
Covers: bruxism defined as repetitive jaw-muscle activity (clenching, grinding, bracing, thrusting), split into sleep and awake bruxism; in otherwise healthy people a behaviour rather than a disorder, though one that can be a risk factor for consequences in teeth, muscles and joints — the “awake and asleep” sub-label
-
Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017;69(2):200-235.
Covers: the reference pharmacology review — binding and entry into the motor nerve terminal, cleavage of SNAP-25 by the type A light chain, block of acetylcholine release at the neuromuscular junction, and the time course of recovery — the “every clench starts at a tiny junction” and “cuts a docking protein” beats
-
Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12(8):535-549.
Covers: neuronal binding, internalization and proteolysis of the SNARE proteins that dock and release neurotransmitter packets; type A toxin cleaves SNAP-25 — the protein named in shot 4
-
de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96(6):3200-3205.
Covers: an animal (mouse) study — after the toxin blocks release, the terminal grows nerve sprouts; by day 28 stimulation again produces contraction, carried first by the sprouts and later by the recovered original terminals — the “the nerve sprouts new endings and the strength returns” beat
-
Ahn KY, Kim ST. The change of maximum bite force after botulinum toxin type A injection for treating masseteric hypertrophy. Plast Reconstr Surg. 2007;120(6):1662-1666.
Covers: in 7 patients treated for masseter enlargement, maximum bite force was significantly reduced at 2, 4 and 8 weeks and back to baseline by 12 weeks — a small study behind “chewing tires sooner, then strength returns”
PubMed · PMID 18040203 · DOI · 10.1097/01.prs.0000282309.94147.22
-
Li K, Tan K, Yacovelli A, Bi WG. Effect of botulinum toxin type A on muscular temporomandibular disorder: A systematic review and meta-analysis of randomized controlled trials. J Oral Rehabil. 2024;51(5):886-897.
Covers: 15 randomized trials, 504 participants — pain on a 0 to 10 scale about 1.9 points lower than placebo at 1 month and 2.1 points lower at 6 months, masseter EMG activity lower at 1 month, occlusal force about 30 kg lower at 3 months, no difference in adverse events versus placebo — the “relief in trials is modest” beat
-
De la Torre Canales G, Câmara-Souza MB, Ernberg M, Al-Moraissi EA, Grigoriadis A, Poluha RL, Christidis M, Jasim H, Lövgren A, Christidis N. Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews. Drugs. 2024;84(7):779-809.
Covers: 18 systematic reviews — botulinum toxin A more effective than placebo for pain but not shown better than standard treatments, not superior for jaw movement, and carrying a higher risk of adverse effects on muscle and bone than other treatments; the authors recommend it as the last treatment alternative — the “a guard, therapy and habit work come first” beat
-
Machado D, Martimbianco ALC, Bussadori SK, Pacheco RL, Riera R, Santos EM. Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis. J Pain. 2020;21(3-4):281-293.
Covers: 12 randomized trials — versus placebo, pain about 1.7 points lower (0 to 10) at 1 month in a pooled analysis of 3 trials and 60 participants, not sustained at later time points; low-quality evidence that, in the authors' words, precludes recommendations for practice — the “modest, and wears off” beat
-
Cruse B, Dharmadasa T, White E, Hollis C, Evans A, Sharmin S, Kalincik T, Kiers L. Efficacy of botulinum toxin type A in the targeted treatment of sleep bruxism: a double-blind, randomised, placebo-controlled, cross-over study. BMJ Neurol Open. 2022;4(2):e000328.
Covers: 22 people analysed — EMG-measured bruxism events per hour lower at 4 weeks after active treatment than placebo, not sustained at 12 weeks; no difference in self-reported headache, pain or bruxism at any time point; five mild, transient side effects — measured clenching falls, symptoms may not
-
Mathew PG, Romero-Reyes M, Virk AS, Manrriquez SL, Duarte RA, Teruel A, Merrill RL, Robertson CE, Tanenbaum D, Cohen R. The Management of Myogenous Temporomandibular Disorders with Botulinum Toxin: A Narrative Review and Management Recommendations. Curr Pain Headache Rep. 2026;30(1):26.
Covers: onabotulinumtoxinA is widely used for TMD despite not being FDA-approved for it; no standardized protocols; may help myogenous TMD and significant bruxism that has not responded to conventional therapy; potential long-term risks (loss of bone density, changes in muscle structure) with no prospective long-term studies; described as neither first-line treatment nor standard of care — the “last resort, not first step” title. Disclosure: the lead author reports consulting for AbbVie
-
Peng HP, Peng JH. Complications of botulinum toxin injection for masseter hypertrophy: Incidence rate from 2036 treatments and summary of causes and preventions. J Cosmet Dermatol. 2018;17(1):33-38.
Covers: 680 patients and 2,036 sessions treated for masseter enlargement (a cosmetic indication) — temporary decrease in chewing force after 30% of sessions, bruising 2.5%, headache 0.58%, paradoxical bulging 0.49%, sunken cheeks 0.44%, sagging 0.20%, smile limitation 0.15% — the “chewing tires” and “rarely, a smile pulls unevenly or a cheek hollows” beats
-
Raphael KG, Tadinada A, Bradshaw JM, Janal MN, Sirois DA, Chan KC, Lurie AG. Osteopenic consequences of botulinum toxin injections in the masticatory muscles: a pilot study. J Oral Rehabil. 2014;41(8):555-563.
Covers: cone-beam CT of the condyles in 7 TMD patients with two or more recent masticatory-muscle injections showed decreased trabecular density in all 7, and in none of 9 unexposed patients; the authors call for replication — one half of “bone under a rested muscle is still being studied”
-
Owen M, Gray B, Hack N, Perez L, Allard RJ, Hawkins JM. Impact of botulinum toxin injection into the masticatory muscles on mandibular bone: A systematic review. J Oral Rehabil. 2022;49(6):644-653.
Covers: 7 human CT or cone-beam CT studies, 5 reporting significant bony changes (condylar head, coronoid, ramus: reduced volume, cortical thickness or density); small samples and very low quality of evidence; dose-dependence unconfirmed
-
Raphael KG, Janal MN, Tadinada A, Santiago V, Sirois DA, Lurie AG. Effect of multiple injections of botulinum toxin into painful masticatory muscles on bone density in the temporomandibular complex. J Oral Rehabil. 2020;47(11):1319-1329.
Covers: 35 women with two or more treatment cycles versus 44 unexposed, all with myofascial TMD — no clinically significant TMJ bone-related changes; within the treated group, higher temporalis dose was inversely related to trabecular density of the mandibular body; doses were smaller than in most trials — the other half of “still being studied”
-
Kostenuik P, Mallya SM, Hopfinger R, Aghaloo T, Gonzalez S, Mah J, Ahmad M, Pan G, Faletto DL, Lee E, Bowen B, Brin MF. Longitudinal Computed Tomography Indicates No Negative Impact of OnabotulinumtoxinA on Mandibular Bone Density in a 12-Month, Double-Blind, Randomized, Repeat Treatment, Placebo-Controlled Study in Healthy Adults With Masseter Muscle Prominence. Aesthet Surg J. 2025;46(1):76-85.
Covers: a prespecified sub-population (123 adults) of a Phase 2 study of masseter muscle prominence — one or two bilateral treatments versus placebo; CT at baseline, day 90 and day 360 showed no clinically significant change in mandibular bone density (condyle, premolar region, ramus). Disclosure: industry-funded (Allergan Aesthetics, an AbbVie company)
-
BOTOX® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use — US Prescribing Information. Allergan, Inc. (an AbbVie company). DailyMed, U.S. National Library of Medicine; current label.
Covers: the list of approved indications, which does not include temporomandibular disorders, bruxism, jaw clenching or masseter reduction — so the use in this film is off-label — and the boxed warning for distant spread of toxin effect: swallowing and breathing difficulties, which can be life-threatening, and generalized weakness have been reported hours to weeks after injection — the “trouble swallowing or breathing means call your doctor” beat
-
Allergan Aesthetics, an AbbVie company. U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence. Press release, August 4, 2026.
Covers: the FDA accepted for review a supplemental application for BOTOX Cosmetic in masseter muscle prominence (a cosmetic, jaw-slimming indication), supported by two Phase 3 studies; under review, not approved, and no decision date was given — why this page says “under FDA review for jaw slimming” and never “approved”